Pharmacotherapeutic follow-up of patients with Chagas disease using in use of benznidazole: drug-related problems and pharmaceutical interventions

Imagem de Miniatura
Arquivos
art_CORREIA_Pharmacotherapeutic_followup_of_patients_with_Chagas_disease_using_2017.PDF (863.17 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2017
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SOC BRASILEIRA MEDICINA TROPICAL
Autores
CORREIA, Joao Paulo Ramalho
COSTA, Alanna Carla da
ROCHA, Eduardo Arrais
QUIDUTE, Ana Rosa Pinto
PONCIANO, Angela Maria de Souza
FONTELES, Marta Maria de Franca
OLIVEIRA, Maria de Fatima
Citação
REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, v.50, n.3, p.334-340, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Introduction: Benznidazole (BNZ) is a drug available for the etiological treatment of Chagas disease. However, this drug is toxic and has a limited effectiveness on the chronic phase of this disease, often leading to poor treatment adherence. Methods: This is a descriptive and exploratory study conducted at the Pharmaceutical Care Service for Chagas disease patients of the Federal University of Ceara. Drug-related problems (DRPs) and pharmaceutical interventions (PIs) were classified according to the Second Consensus of Granada. Results: The average age of patients with Chagas disease was 62 years, with the majority residing in the Ceara countryside (86.7%), and having low education levels (63.3% with elementary school education). Regarding family income, most patients belonged to a household that earned <= 1-2 times the minimum wage per month. Approximately 73% of these patients complied with the BNZ treatment, and nearly 7% underwent therapy interruption after medical evaluation. A total of 189 DRPs were identified, of which 51.9% (n=98) were classified as potential, and 48.1% (n= 91) as actual. The most frequent DRPs were related to safety (qualitative safety; n=70; 37%), necessity (non-adherence; n=52; 27.5%), and effectiveness (qualitative effectiveness/non-optimal drug selection; n=45; 23.8%). Among the 216 PIs conducted, the majority were related to patient education (n=168; 77.8%) and pharmacological strategy (n=42; 19.4%). Conclusions: This study indicates the need for pharmacotherapeutic monitoring in patients with Chagas because of the high number of therapeutic interventions, DRPs (approximately 3 DRPs/patient), BNZ adherence, and polypharmacy.
Palavras-chave
Chagas disease, Pharmaceutical care, Pharmacotherapy
URI
https://observatorio.fm.usp.br/handle/OPI/22032
Referências
  1. Aizenstein M. L., 2011, Revista de Ciencias Farmaceuticas Basica e Aplicada, V32, P167
  2. Carrilero B, 2011, REV ESP QUIM, V24, P123
  3. Centers for Disease Control and Prevention, 2013, EP RISK FACT
  4. Correr Cassyano Januario, 2007, Revista Brasileira de Ciencias Farmaceuticas, V43, P55
  5. Coura JR, 2009, MEM I OSWALDO CRUZ, V104, P31, DOI 10.1590/S0074-02762009000900006
  6. Guedes P. M. M., 2006, Anti-Infective Agents in Medicinal Chemistry, V5, P175, DOI 10.2174/187152106776359020
  7. Hepler CD, 1999, PHARM CARE ESP, V1, P35
  8. Hernandez DS, 2014, METODO DADER MANUAL
  9. Jaber LA, 1996, ANN PHARMACOTHER, V30, P238
  10. JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949
  11. Marinker M, 2003, BRIT MED J, V326, P348, DOI 10.1136/bmj.326.7385.348
  12. Moreira LB, 2008, REV BRAS CIENC FARM, V44, P315, DOI 10.1590/S1516-93322008000200017
  13. Morillo CA, 2015, NEW ENGL J MED, V373, P1295, DOI 10.1056/NEJMoa1507574
  14. Morris CJ, 2003, J CLIN PHARM THER, V28, P295, DOI 10.1046/j.1365-2710.2003.00496.x
  15. Organizacion Panamericana de la Salud, 2006, OPSHDMCD42506
  16. Pereira LD, 2015, REV INST MED TROP SP, V57, P145, DOI 10.1590/S0036-46652015000200008
  17. Piegas LS, 2009, ARQ BRAS CARDIOL S2, V93, pe179
  18. Dias JCP, 2016, EPIDEMIOL SERV SAUDE, V25, P7, DOI 10.5123/S1679-49742016000500002
  19. Pontes Vânia Maria Oliveira de, 2010, Rev. Soc. Bras. Med. Trop., V43, P182, DOI 10.1590/S0037-86822010000200015
  20. Rosa Mário Borges, 2003, Rev. Assoc. Med. Bras., V49, P335, DOI 10.1590/S0104-42302003000300041
  21. Sabater D, 2005, SEGUIM FARMACOTER, V3, P90
  22. Santos H, 2004, ACTA MEDICA PORT, V17, P56
  23. Schmunis GA, 2010, ACTA TROP, V115, P14, DOI 10.1016/j.actatropica.2009.11.003
  24. Silva FM, 2008, REV MED, V87, P213
  25. SKAER TL, 1993, J CLIN PHARM THER, V18, P295, DOI 10.1111/j.1365-2710.1993.tb00591.x
  26. Souza-Junior AS, 2009, CAD SAUDE COLET, V17, P893
  27. Storino R, 1998, REV ARGENT CARDIOL, V66, P17
  28. VANVELDHUIZENSCOTT MK, 1995, DIABETES EDUCATOR, V21, P117, DOI 10.1177/014572179502100207
  29. Varma S, 1999, PHARMACOTHERAPY, V19, P860, DOI 10.1592/phco.19.10.860.31565
  30. World Health Organization, 2010, WKLY EPIDEMIOL REC, V85, P334
  31. World Health Organization, 2012, WKLY EPIDEMIOL REC, V87, P519

Coleções
Artigos e Materiais de Revistas Científicas - FM/Outros
Artigos e Materiais de Revistas Científicas - LIM/19
Artigos e Materiais de Revistas Científicas - ODS/08
Artigos e Materiais de Revistas Científicas - ODS/10